Developments IN8bio reports sustained PFS in INB-100 trial for HSCT patients IN8bio (NASDAQ:INAB) shared updated data showcasing continued progression-free survival (PFS) from its Phase 1 trial of INB-100 in older patients with hematologic malignancies undergoing haploidentical stem cell... December 10, 2024